1H-Imidazole, 4-cyclopropyl-1-(1-methylethyl)- | 1337606-47-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1H-Imidazole, 4-cyclopropyl-1-(1-methylethyl)-
• 英文别名: 4-cyclopropyl-1-propan-2-ylimidazole
• CAS: 1337606-47-9
• 化学式: C₉H₁₄N₂
• 分子量: 150.22
• InChiKey: VVUBVSYKXUHJEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Cyclobutyl-Imidazolidinone Compounds
  申请人：Eli Lilly and Company

  公开号：US20190071413A1

  公开（公告）日：2019-03-07

  The present invention provides a compound of Formula I wherein Q is selected from the group consisting of —CH(CH 3 ) 2 and R is selected from the group consisting of or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH.

  本发明提供了一种化合物，其化学式为I，其中Q从以下群体中选择，即-CH(CH3)2，R从以下群体中选择，即或其药用盐；组合物，治疗肝病和NASH的方法。
• Cyclobutyl-imidazolidinone compounds
  申请人：Eli Lilly and Company

  公开号：US10370352B2

  公开（公告）日：2019-08-06

  The present invention provides a compound of Formula I wherein Q is selected from the group consisting of —CH(CH3)2 and R is selected from the group consisting of or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH.

  本发明提供了一种式 I 的化合物 其中 Q 选自-CH(CH3)2 和 R 选自以下组别 或 或其药学上可接受的盐；治疗肝病和 NASH 的组合物和方法。
• Imidazolidine compounds
  申请人：Eli Lilly and Company

  公开号：US11124496B2

  公开（公告）日：2021-09-21

  The present invention provides a compound of Formula (I) wherein X is selected from the group consisting of (CH2)2— and CH2—CH(CH3)—; Q is selected from the group consisting of C(CH3)2 and Formula (a); or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH.

  本发明提供了式(I)化合物，其中X选自由(CH2)2-和 -CH(CH3)-组成的组；Q选自由C( )2和式(a)组成的组；或其药学上可接受的盐；治疗肝病和NASH的组合物和方法。
• Isoquinolin and naphthydrin compounds
  申请人：Eli Lilly and Company

  公开号：US11117891B2

  公开（公告）日：2021-09-14

  The present invention provides a compound of Formula II wherein X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of and; or a pharmaceutically acceptable salt thereof, compositions, methods to treat liver disease and NASH.

  本发明提供了一种式 II 的化合物，其中 X 选自 CH 和 N 组成的组；Q 选自 CH3 和 H 组成的组；R 选自 和 组成的组；或其药学上可接受的盐、组合物、治疗肝病和 NASH 的方法。
• ISOQUINOLIN AND NAPHTHYDRIN COMPOUNDS
  申请人：Eli Lilly and Company

  公开号：US20200062751A1

  公开（公告）日：2020-02-27

  The present invention provides a compound of Formula I I wherein X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of and; or a pharmaceutically acceptable salt thereof, compositions, methods to treat liver disease and NASH.